Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study Phase II / III, multicenter, double-masked, randomized, parallel Group, with variations of dose, controlled to evaluate the efficacy and safety of NOVA22007 (eye cationic emulsion of Cyclosporine A (CSA) 00:05% and 0.1%) vs. vehicle in patients with vernal queratoconjonctivitis. [Estudio de fase II/III, Multicentrico, doble enmascarado, Aleatorizado, de Grupos paralelos, Con variacion de dosis, controlado para valorar la eficacia y seguridad de NOVA22007 (emulsion ocular cationica de Ciclosporina A (CSA) 0.05% y 0.1%) frente a vehiculo en pacientes con queratoconjonctivitis vernal.]

Trial Profile

Study Phase II / III, multicenter, double-masked, randomized, parallel Group, with variations of dose, controlled to evaluate the efficacy and safety of NOVA22007 (eye cationic emulsion of Cyclosporine A (CSA) 00:05% and 0.1%) vs. vehicle in patients with vernal queratoconjonctivitis. [Estudio de fase II/III, Multicentrico, doble enmascarado, Aleatorizado, de Grupos paralelos, Con variacion de dosis, controlado para valorar la eficacia y seguridad de NOVA22007 (emulsion ocular cationica de Ciclosporina A (CSA) 0.05% y 0.1%) frente a vehiculo en pacientes con queratoconjonctivitis vernal.]

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Sep 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Santen S.A.S.
  • Most Recent Events

    • 09 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top